This article is more than 5 years old. Information may no longer be current.

Bausch & Lomb licenses plasmin derivative for ophthalmic use

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — Talecris Biotherapeutics has granted Bausch & Lomb the exclusive worldwide rights to codevelop rPlasmin, a recombinant derivative of human blood plasmin that may have ophthalmic applications, the companies announced.

The agreement expands upon Bausch & Lomb's earlier licensing of plasma-derived rPlasmin from Talecris' predecessor, Bayer Biological Products, in January 2005. Under the new agreement, Bausch & Lomb will be responsible for ophthalmic development of the drug and will make milestone payments based on development and registration progress. It will also pay ongoing royalties based on product sales.

Bausch & Lomb is enrolling patients in early-stage clinical trials to evaluate the drug's potential to relieve retinal tractions, according to a press release.